EHA2021 virtual, the Annual Congress of the European Hematology Association (EHA) - offered a full scientific program from 9 until 17 June. On 9 July and 16 July, EHA will organize multiple EHA2021 Follow-up days, during which new content is released.
The HARMONY Alliance will be part of the Follow-up day: “Big data for clinicians”, which is organized at 9 July in the afternoon. The EHA2021 congress platform is accessible until 15 August. EHA is a HARMONY Partner. Read more about EHA2021 >
More information, program an registration >
In hematology, we have been using Big Data to develop precision diagnostics and precision medicine approaches in blood cancer treatment for a long time already. We have been using genetic diagnostics to stratify patients in order to select the right treatment for the right patient. In addition, Hematologic Malignancies were among the first diseases where targeted therapies were implemented. One of the driving forces behind precision medicine in hematology is the HARMONY Alliance: a Public-Private Partnership for Big Data in Hematology. Funded by the Innovative Medicines Initiative (IMI) of the EU, HARMONY unites more than 100 European organizations, varying from medical associations and hospitals, to research institutes, patient organizations, pharmaceutical companies, and more.
How to participate in the live session of 9 July?
The HARMONY Alliance is an EHA2021 conference partner. HARMONY experts demonstrate the potential of big data to improve the treatment of hematologic malignancies in varous conference program features.Since the HARMONY launch in 2017, EHA invited HARMONY to participate in the EHA annual congresses.
About the EHA2021 Follow Up Days:
#bigdataforbloodcancer: Big Data analytics will accelerate better and faster treatment
The HARMONY Alliance is a European Public–Private Partnership for Big Data in Hematology that is capturing and mining Big Data on various Hematologic Malignancies/blood cancers. The HARMONY Alliance unites more than 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies.
HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Data are stored in HARMONY’s Big Data Platform, which has already identified over 70,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods.
Join the HARMONY Alliance: watch the video and/or contact us now >
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
